ImmuCell Corporation Q1 2023 Earnings Call

We're sort of rebooting the production process from start to finish from farm to finished goods, but that data is shared does give some indication that we're in very good shape in the mid process very good shape, but the end process with 100%.

Meeting specs and still a bit focused on that front end and we will continue to be.

To move that 88% up to a much higher number I don't know if it needs to be at a 100, but it will move it up from 80 889, where it is today higher and that's so I guess my answer is are we focused farm to finish start the start to the end.

But we've got some more work to do on the front end right. So.

It sounds like you can get closer to a 100% I mean, it was impossible to actually eradicate this issue with the with new procedures.

You know I don't think so I mean, we wanted to get as close to a hunter as possible, there's definitely room for more improvement, but we have to be cognizant that we're dealing with.

With with a dirty raw material it is and it does come from a from a barn.

And they know our specs are set up to allow them to to to anticipate that so it's not a septic, it's certainly not sterile, but it needs to be held below the.

The the.

Standards, the specification level and what happened in this contamination of some of these batches popped up above that level. So we need to just move it down so theres a margin between wherever we operate and where that that line is on pass fail.

Thank you and again if you have a question. Please press Star then one.

Yeah.

Okay. Since we do not seem to have any other questions queuing up I would like to thank everybody for participating in today's call and we look forward to talking with you again to review.

The results of the second quarter of 2023 on or about August a lot of them have a great day.

The conference has now concluded. Thank you for attending today's presentation you may now disconnect.

[music].

Yeah.

[music].